Skip to main content
. Author manuscript; available in PMC: 2018 Jul 20.
Published in final edited form as: Nat Rev Clin Oncol. 2016 Mar 8;13(8):516–524. doi: 10.1038/nrclinonc.2016.30

Table 2.

Selected ongoing clinical trials investigating the efficacy of ISABR

Institution and study details SABR dose (Gy)/fraction SABR Target Immunotherapy agent Sequence of treatments Phase
Johns Hopkins University, NCT0195019546 NS Brain, Spine Ipilimumab Immunotherapy, then SABR, then immunotherapy I
University of Pennsylvania, NCT01497808 (RADVAX)47 NS NS Ipilimumab SABR then immunotherapy I/II
MD Anderson Cancer Center, NCT0223990048 50/4
60/10		 Liver, Lung, Adrenal Ipilimumab Concurrent, or immunotherpy then SABR I/II
Chiles Research Institute, NCT0186290071 15/1
20/1		 Lung, Liver Anti-OX40 Concurrent I/II
Stanford University, NCT0176922272 20/2 Any Ipilimumab Concurrent I/II
New York University, NCT0140106273 22.5/3 Any Fresolimumab Concurrent I/II
NIH/NCI, NCT0229894674 8/1
24/3		 Liver PD-1 inhibitor SABR then immunotherapy I
Thomas Jefferson University, NCT0170350775 24/1
21/1
18/1
15/1		 Brain Ipilimumab Concurrent I
MD Anderson Cancer Center, NCT0244474176 50/4 Lung, Liver PD-1 inhibitor Concurrent I/II

ISABR; Immunotherapy combined and stereotactic ablative radiotherapy; SABR, stereotactic ablative radiotherapy; NCI, National Cancer Institute; NS, not specified.